Holen Sie sich die Stockscreener-App
6.10
1.50%
0.09
Handel nachbörslich:
6.24
0.14
+2.30%
Schlusskurs vom Vortag:
$6.01
Offen:
$6.03
24-Stunden-Volumen:
375.89K
Relative Volume:
0.48
Marktkapitalisierung:
$334.88M
Einnahmen:
$124.00K
Nettoeinkommen (Verlust:
$-49.99M
KGV:
-3.6095
EPS:
-1.69
Netto-Cashflow:
$-31.03M
1W Leistung:
+3.04%
1M Leistung:
+1.50%
6M Leistung:
-13.11%
1J Leistung:
-5.86%
1-Tages-Spanne:
$5.98
$6.15
1-Wochen-Bereich:
$5.91
$6.62
52-Wochen-Spanne:
$4.25
$13.68
Candel Therapeutics Inc Stock (CADL) Company Profile
Firmenname
Candel Therapeutics Inc
Sektor
Branche
Telefon
617-916-5445
Adresse
117 KENDRICK STREET, NEEDHAM
Vergleichen Sie CADL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
6.10 | 329.94M | 124.00K | -49.99M | -31.03M | -1.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-28 | Eingeleitet | Stephens | Overweight |
| 2025-09-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-06-30 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-02-20 | Eingeleitet | Citigroup | Buy |
| 2025-02-19 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-02-07 | Eingeleitet | BofA Securities | Buy |
| 2022-12-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-08-23 | Eingeleitet | Credit Suisse | Outperform |
| 2021-08-23 | Eingeleitet | Jefferies | Buy |
| 2021-08-23 | Eingeleitet | UBS | Buy |
Alle ansehen
Candel Therapeutics Inc Aktie (CADL) Neueste Nachrichten
What is the earnings history of Candel Therapeutics Inc.Insider Selling & Precise Trade Entry Recommendations - mfd.ru
Oncolytic Virotherapy Market - GlobeNewswire Inc.
Candel Therapeutics (NASDAQ:CADL) Stock Rating Lowered by Zacks Research - MarketBeat
New Strong Sell Stocks for January 20th - sharewise.com
Is Candel Therapeutics Inc. stock affected by interest rate hikesQuarterly Growth Report & Growth Focused Investment Plans - bollywoodhelpline.com
Trading the Move, Not the Narrative: (CADL) Edition - Stock Traders Daily
Breakeven On The Horizon For Candel Therapeutics, Inc. (NASDAQ:CADL) - simplywall.st
Aug Highlights: Will Xometry Inc stock recover after earningsPortfolio Risk Report & Pattern Based Trade Signal System - baoquankhu1.vn
Loss-Making Candel Therapeutics, Inc. (NASDAQ:CADL) Expected To Breakeven In The Medium-Term - Yahoo Finance
Sectors Review: Will Candel Therapeutics Inc stock maintain momentum in 2025Earnings Trend Report & Consistent Profit Alerts - Bộ Nội Vụ
Valuation Update: Will Candel Therapeutics Inc. stock outperform tech sector in 2025IPO Watch & Consistent Profit Trade Alerts - Улправда
Can Candel Therapeutics Inc. stock attract ESG capital inflows2025 Momentum Check & Consistent Return Strategy Ideas - ulpravda.ru
Aug Volume: Will Candel Therapeutics Inc. stock outperform tech sector in 20252025 Analyst Calls & Free Weekly Chart Analysis and Trade Guides - Улправда
Can Candel Therapeutics Inc. stock sustain free cash flow growth2025 Valuation Update & Trade Opportunity Analysis - Улправда
Will Candel Therapeutics Inc. stock outperform tech sector in 2025IPO Watch & Consistent Profit Trade Alerts - Улправда
Analysts Offer Insights on Healthcare Companies: Candel Therapeutics (CADL) and Stereotaxis (STXS) - The Globe and Mail
(CADL) Volatility Zones as Tactical Triggers - Stock Traders Daily
Candel Therapeutics, Inc. (NASDAQ:CADL) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Understanding the Setup: (CADL) and Scalable Risk - Stock Traders Daily
Candel Therapeutics, Inc.(NasdaqGM: CADL) added to NASDAQ Biotechnology Index - marketscreener.com
Can Candel Therapeutics Inc. stock surprise with earnings upside2025 Momentum Check & Risk Adjusted Buy/Sell Alerts - Улправда
Candel Therapeutics Earnings Notes - Trefis
Why Candel Therapeutics Inc. stock is rated strong buyOil Prices & Stepwise Swing Trade Plans - Улправда
Will Candel Therapeutics Inc. stock outperform Dow Jones index2025 AllTime Highs & Long-Term Capital Growth Ideas - DonanımHaber
Will Candel Therapeutics Inc. stock maintain growth storyStop Loss & AI Powered Buy and Sell Recommendations - Улправда
Bear Alert: Why Candel Therapeutics Inc. stock is rated strong buyWeekly Gains Summary & Weekly Breakout Watchlists - Улправда
How (CADL) Movements Inform Risk Allocation Models - Stock Traders Daily
B of A Securities Downgrades Candel Therapeutics (CADL) - MSN
Candel Therapeutics, Inc. $CADL is Acorn Capital Advisors LLC's 5th Largest Position - MarketBeat
Is Candel Therapeutics On The Move With Pipeline Progress And Market Momentum? - RTTNews
Diamond Hill Investment Group, Rhythm Pharmaceuticals, Vail Resorts And Other Big Stocks Moving Higher On Thursday - Benzinga
Brookline Capital Management Weighs in on CADL Q4 Earnings - MarketBeat
Citi Maintains Candel Therapeutics(CADL.US) With Buy Rating, Maintains Target Price $24 - 富途牛牛
Candel Therapeutics (NASDAQ:CADL) Shares Little Changed on Clinical-Stage Progress - Kalkine Media
Stephens Reaffirms Overweight Rating for Candel Therapeutics (NASDAQ:CADL) - MarketBeat
Candel Therapeutics, Inc. (NASDAQ:CADL) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Candel Therapeutics (CADL) Maintains "Overweight" Rating by Step - GuruFocus
CADL: CAN-2409's phase 3 success and strong market outlook drive launch readiness and pipeline expansion - TradingView
CADL: CAN-2409's phase III success and strong market readiness position it for rapid adoption and growth - TradingView — Track All Markets
CADL: Late-stage immunotherapy programs advance toward commercialization and regulatory milestones - TradingView — Track All Markets
Candel Therapeutics, Inc. Hosts R&D Day Highlighting Viral Immunotherapy Advances - TradingView — Track All Markets
Candel Therapeutics, Inc. (CADL) Stock Analysis: Unveiling a 271% Potential Upside in Biotech - directorstalkinterviews.com
How Candel Therapeutics Inc. stock trades before earningsJuly 2025 Sentiment & AI Driven Stock Price Forecasts - Newser
Is Candel Therapeutics Inc. stock recession proof2025 Price Targets & Long-Term Capital Growth Strategies - Newser
Candel Therapeutics (CADL) Stock Analysis Report | Financials & Insights - Benzinga
Is Candel Therapeutics Inc. stock attractive after correctionWeekly Volume Report & AI Forecast for Swing Trade Picks - Newser
Is Candel Therapeutics Inc. stock resilient to inflationPortfolio Update Summary & Safe Capital Investment Plans - Newser
Candel: lighting the path to a brighter future for patients with solid tumors - Nature
Candel Therapeutics (CADL) Upgraded to Strong Buy: Here's What You Should Know - MSN
Candel Therapeutics Stock Headed For 20% Weekly Gains: Retail Over The Moon With BofA's 'Buy' Call - MSN
Candel Therapeutics stock price target raised to $14 by Freedom Capital - Investing.com Nigeria
Finanzdaten der Candel Therapeutics Inc-Aktie (CADL)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.09%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):